Adynxx announced that the FDA has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain. AYX1 is an investigational drug designed to reduce acute post-surgical pain and prevent the transition to persistent or chronic pain with a single administration at the time of surgery.
The Adynxx platform utilizes a proprietary form of oligonucleotide technology – small, synthetic pieces of DNA that bind to transcription factors and inhibit their activity. Transcription factors directly and specifically regulate the expression of a large number of proteins. In pain pathways, they are essential triggers for the expression of multiple and redundant pain-related proteins.
In September 2012 Adynxx completed a 30-subject, dose-escalating study of AYX1 in five cohorts of healthy volunteers. Adynxx is currently enrolling a 90 patient placebo-controlled Phase 2 study to evaluate the safety and efficacy of a single administration of AYX1 given prior to unilateral total knee arthroplasty (TKA) to reduce or prevent post-surgical pain.
For more information call (415) 512-7740 or visit www.adynxx.com.